{"id":"W4283373229","doi":"10.1101/2022.02.17.22271120","title":"Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; University of Toronto; University Health Network; McGill University Health Centre; Jewish General Hospital","funders":"Daiichi Sankyo Europe; National Cancer Institute; Fonds de Recherche du Québec - Santé; Foundation Medicine; Bayer Yakuhin; Chugai Pharmaceutical; EMD Serono; PharmaMar; Eisai; University of Texas MD Anderson Cancer Center; Insmed; BeiGene; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Array BioPharma; Jazz Pharmaceuticals; Conquer Cancer Foundation; Merck KGaA; Taiho Pharmaceutical; Karyopharm Therapeutics; Exelixis; Sanofi; National Institutes of Health; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; GlaxoSmithKline; Yakult Honsha; American Society of Clinical Oncology; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Symphogen; Moderna; Incyte; Pfizer; Genentech; Aeglea BioTherapeutics; Helsinn Therapeutics; Amgen; Clovis Oncology; Melanoma Research Alliance; AIM at Melanoma; Daiichi Sankyo Company; American Cancer Society","keywords":"Medicine; Targeted therapy; MAPK/ERK pathway; Oncology; Lung cancer; Cancer; Melanoma; Internal medicine; Cancer research; Kinase; Biology; Genetics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007737581,0.0009801652,0.006599874,0.002987633,0.0002442596,0.001778524,0.0008865606,0.001029376,0.001788711],"category_scores_gemma":[0.01789849,0.0005505746,0.01607365,0.003304054,0.0003630858,0.0009833374,0.0005502987,0.0009983686,0.0001618026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001155846,"about_ca_system_score_gemma":0.0009874584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002005181,"about_ca_topic_score_gemma":0.004629096,"domain_scores_codex":[0.9943516,0.002566352,0.001731726,0.0006504901,0.0005648911,0.0001348552],"domain_scores_gemma":[0.9798244,0.01552342,0.003329662,0.0003795779,0.0007996967,0.000143378],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"observational","study_design_scores_codex":[0.006925154,0.00005699952,0.02368879,0.3041642,0.6133321,0.000164535,0.0001003508,0.00118901,0.0008584443,0.000196736,0.001107451,0.04821629],"study_design_scores_gemma":[0.001369323,0.00112486,0.03238335,0.03119771,0.9270056,0.000390646,0.0001037599,0.0004073036,0.0007342181,0.0004366147,0.004809351,0.00003732497],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.01337684,0.9850874,0.0002282115,0.0001688533,0.00007215986,0.00008805071,0.0005357512,0.00001072535,0.0004320736],"genre_scores_gemma":[0.5332373,0.4629734,0.001072727,0.0008987898,0.0002980497,0.0002863031,0.0009637274,0.0000231767,0.0002466691],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.007737581,"threshold_uncertainty_score":0.04092073,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0132778112205065,"score_gpt":0.2615942006891303,"score_spread":0.2483163894686238,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}